Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia
Leukemia, Lymphocytic, Chronic, B-Cell
Ibrutinib, as compared with ofatumumab, significantly improved progression-free survival, overall survival, and response rate among patients with previously treated CLL or SLL. (Funded by Pharmacyclics and Janssen; RESONATE ClinicalTrials.gov number, NCT01578707.).